Skip to main content
SpringerLink
Log in
Book cover

Energy Balance and Hematologic Malignancies pp 129–140Cite as

The Impact of Obesity on Stem Cell Transplant

  • Chapter
  • First Online:

Part of the book series: Energy Balance and Cancer ((EBAC,volume 5))

Abstract

Hematopoietic cell transplantation (HCT) is a high-risk procedure of curative potential for patients with various malignant and nonmalignant hematological diseases. Because the procedure carries considerable risks of treatment-related morbidity and mortality and has variable results in improving disease-free survival, patient selection plays an important role in its success. One patient factor that has received attention in the last 20 years has been the concern that obese patients may not have outcomes similar to normal weight individuals because of (1) altered pharmacokinetics of commonly used chemotherapeutic agents [1, 2], (2) presence of other medical comorbidities with obesity [3], and (3) higher morbidity associated with obesity itself [4], which may result in higher post-HCT morbidity/mortality. Because obesity has become a pandemic affecting both children and adults in the United States and worldwide [5–8], the body of literature evaluating the relationship between obesity and clinical outcomes in the setting of HCT has grown as well. This chapter explores the pharmacokinetics, pharmacodynamics, and clinical outcomes of HCT in the setting of obesity.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49(2):71–87

    Article  PubMed  CAS  Google Scholar 

  2. Jain R, Chung SM, Jain L, Khurana M, Lau SW, Lee JE et al (2011) Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 90(1):77–89

    Article  PubMed  CAS  Google Scholar 

  3. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH (2009) The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9:88

    Article  PubMed  Google Scholar 

  4. Flegal KM, Graubard BI, Williamson DF, Gail MH (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 298(17):2028–37

    Article  PubMed  CAS  Google Scholar 

  5. WHO (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series, vol 894. WHO, Geneva, pp i–xii, 1–253

    Google Scholar 

  6. Kosti RI, Panagiotakos DB (2006) The epidemic of obesity in children and adolescents in the world. Cent Eur J Public Health 14(4):151–9

    PubMed  Google Scholar 

  7. Low S, Chin MC, Deurenberg-Yap M (2009) Review on epidemic of obesity. Ann Acad Med 38(1):57–9

    Google Scholar 

  8. Misra A, Khurana L (2008) Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 93(11 Suppl 1):S9–30

    Article  PubMed  CAS  Google Scholar 

  9. Rodvold KA, Rushing DA, Tewksbury DA (1988) Doxorubicin clearance in the obese. J Clin Oncol 6(8):1321–7

    PubMed  CAS  Google Scholar 

  10. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM (1989) Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol 25(2):139–42

    Article  PubMed  CAS  Google Scholar 

  11. Sparreboom A, Wolff AC, Mathijssen RH, Chatelut E, Rowinsky EK, Verweij J et al (2007) Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol 25(30):4707–13

    Article  PubMed  CAS  Google Scholar 

  12. Grigg A, Harun MH, Szer J (1997) Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey. Leuk Lymphoma 25(5–6):487–91

    PubMed  CAS  Google Scholar 

  13. Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD et al (2001) Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 27(11):1121–4

    Article  PubMed  CAS  Google Scholar 

  14. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al (1996) Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 17(2):225–30

    PubMed  CAS  Google Scholar 

  15. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R et al (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25(1):55–61

    Article  PubMed  CAS  Google Scholar 

  16. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al (1997) Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89(8):3055–60

    PubMed  CAS  Google Scholar 

  17. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR et al (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93(12):4436–40

    PubMed  CAS  Google Scholar 

  18. Nguyen L, Leger F, Lennon S, Puozzo C (2006) Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 57(2):191–8

    Article  PubMed  CAS  Google Scholar 

  19. De Jonge ME, Mathot RA, Van Dam SM, Beijnen JH, Rodenhuis S (2002) Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Cancer Chemother Pharmacol 50(3):251–5

    Article  PubMed  Google Scholar 

  20. Meloni G, Proia A, Capria S, Romano A, Trape G, Trisolini SM et al (2001) Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 28(4):365–7

    Article  PubMed  CAS  Google Scholar 

  21. Tarella C, Caracciolo D, Gavarotti P, Argentino C, Zallio F, Corradini P et al (2000) Overweight as an adverse prognostic factor for non-Hodgkin’s lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplant 26(11):1185–91

    Article  PubMed  CAS  Google Scholar 

  22. Dickson TM, Kusnierz-Glaz CR, Blume KG, Negrin RS, Hu WW, Shizuru JA et al (1999) Impact of admission body weight and chemotherapy dose adjustment on the outcome of autologous bone marrow transplantation. Biol Blood Marrow Transplant 5(5):299–305

    Article  PubMed  CAS  Google Scholar 

  23. Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR (1995) Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 15(3):461–8

    PubMed  CAS  Google Scholar 

  24. Vogl DT, Wang T, Perez WS, Stadtmauer EA, Heitjan DF, Lazarus HM et al (2011) Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 17(12):1765–74

    Article  PubMed  Google Scholar 

  25. Navarro WH, Loberiza FR Jr, Bajorunaite R, van Besien K, Vose JM, Lazarus HM et al (2006) Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 12(5):541–51

    Article  PubMed  Google Scholar 

  26. Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H et al (2010) Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) in adults. Biol Blood Marrow Transplant 16(10):1442–50

    Article  PubMed  Google Scholar 

  27. Pine M, Wang L, Harrell FE Jr, Calder C, Manes B, Evans M et al (2010) The effect of obesity on outcome of unrelated cord blood transplant in children with malignant diseases. Bone Marrow Transplant 46(10):1309–13

    Article  PubMed  Google Scholar 

  28. Barker CC, Agovi MA, Logan B, Lazarus HM, Ballen KK, Gupta V et al (2011) Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant 17(5):737–44

    Article  PubMed  Google Scholar 

  29. Fleming DR, Rayens MK, Garrison J (1997) Impact of obesity on allogeneic stem cell transplant patients: a matched case-controlled study. Am J Med 102(3):265–8

    Article  PubMed  CAS  Google Scholar 

  30. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. New Engl J Med 338(14):962–8

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Marrow Donor Program, 3001 Broadway St NE, Suite 325, Minneapolis, MN, 55413, USA

    Willis H. Navarro

  2. Department of Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE, 68198-7680, USA

    Fausto R. Loberiza Jr. M.D., M.S.

Authors
  1. Willis H. Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fausto R. Loberiza Jr. M.D., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Willis H. Navarro .

Editor information

Editors and Affiliations

  1. Keck School of Medicine, Sunset Blvd., MS #61 4650, Los Angeles, 90027, California, USA

    Steven D. Mittelman

  2. School of Medicine, Center for Science, Health & Society, Case Western Reserve University, Euclid Ave. 10900, Cleveland, 44106, Ohio, USA

    Nathan A. Berger

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Navarro, W.H., Loberiza, F.R. (2012). The Impact of Obesity on Stem Cell Transplant. In: Mittelman, S., Berger, N. (eds) Energy Balance and Hematologic Malignancies. Energy Balance and Cancer, vol 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-2403-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-2403-1_6

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-2402-4

  • Online ISBN: 978-1-4614-2403-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation